Quantitative determination of geranyl diphosphate levels in cultured human cells

Sarah A. Holstein, Huaxiang Tong, Craig H. Kuder, Raymond J. Hohl

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Geranyl diphosphate (GPP), a 10-carbon isoprenoid, is a key intermediate in the isoprenoid biosynthetic pathway. This pathway, in addition to leading to sterol synthesis, results in the synthesis of farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), which serve as substrates for protein isoprenylation reactions. Basal levels of GPP in mammalian cells previously have been undetectable. Here we present a novel, sensitive, nonradioactive method which allows for measurement of GPP in mammalian cells. This methodology involves extraction of isoprenoids from cultured cells followed by enzymatic conjugation of GPP to a fluorescent dansylated-peptide via farnesyl transferase and quantification with high-performance liquid chromatography (HPLC). The lower limit of detection of GPP is 5 pg, or 0.015 pmol. Basal levels of GPP were determined in three human multiple myeloma cell lines (RPMI-8226, U266, H929). Treatment of cells with inhibitors of the isoprenoid biosynthetic pathway results in marked changes in GPP levels: the HMG-CoA reductase inhibitor lovastatin decreases GPP levels by over 50%, while the FPP synthase inhibitor zoledronic acid increases GPP levels 16- to 107-fold. This method also allows for the simultaneous measurement of GPP, FPP, and GGPP, thus leading to improved understanding of the pathway in a multitude of biological systems. Furthermore, as drugs targeting this pathway are developed, their biological activity can be more directly linked to effects on isoprenoid levels.

Original languageEnglish (US)
Pages (from-to)1055-1062
Number of pages8
JournalLipids
Volume44
Issue number11
DOIs
StatePublished - Nov 1 2009

Fingerprint

Terpenes
Cultured Cells
Cells
zoledronic acid
Biosynthetic Pathways
Protein Prenylation
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lovastatin
High performance liquid chromatography
Sterols
Biological systems
Drug Delivery Systems
Transferases
Bioactivity
Multiple Myeloma
Limit of Detection
Carbon
High Pressure Liquid Chromatography
geranyl diphosphate
Cell Line

Keywords

  • Farnesyl diphosphate
  • Fluorescence detection
  • Geranyl diphosphate
  • Geranylgeranyl diphosphate
  • High performance liquid chromatography, isoprenylation
  • Isoprenoid

ASJC Scopus subject areas

  • Biochemistry
  • Organic Chemistry
  • Cell Biology

Cite this

Quantitative determination of geranyl diphosphate levels in cultured human cells. / Holstein, Sarah A.; Tong, Huaxiang; Kuder, Craig H.; Hohl, Raymond J.

In: Lipids, Vol. 44, No. 11, 01.11.2009, p. 1055-1062.

Research output: Contribution to journalArticle

Holstein, Sarah A. ; Tong, Huaxiang ; Kuder, Craig H. ; Hohl, Raymond J. / Quantitative determination of geranyl diphosphate levels in cultured human cells. In: Lipids. 2009 ; Vol. 44, No. 11. pp. 1055-1062.
@article{70d061f1d3354925902f14a0b3bd3deb,
title = "Quantitative determination of geranyl diphosphate levels in cultured human cells",
abstract = "Geranyl diphosphate (GPP), a 10-carbon isoprenoid, is a key intermediate in the isoprenoid biosynthetic pathway. This pathway, in addition to leading to sterol synthesis, results in the synthesis of farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), which serve as substrates for protein isoprenylation reactions. Basal levels of GPP in mammalian cells previously have been undetectable. Here we present a novel, sensitive, nonradioactive method which allows for measurement of GPP in mammalian cells. This methodology involves extraction of isoprenoids from cultured cells followed by enzymatic conjugation of GPP to a fluorescent dansylated-peptide via farnesyl transferase and quantification with high-performance liquid chromatography (HPLC). The lower limit of detection of GPP is 5 pg, or 0.015 pmol. Basal levels of GPP were determined in three human multiple myeloma cell lines (RPMI-8226, U266, H929). Treatment of cells with inhibitors of the isoprenoid biosynthetic pathway results in marked changes in GPP levels: the HMG-CoA reductase inhibitor lovastatin decreases GPP levels by over 50{\%}, while the FPP synthase inhibitor zoledronic acid increases GPP levels 16- to 107-fold. This method also allows for the simultaneous measurement of GPP, FPP, and GGPP, thus leading to improved understanding of the pathway in a multitude of biological systems. Furthermore, as drugs targeting this pathway are developed, their biological activity can be more directly linked to effects on isoprenoid levels.",
keywords = "Farnesyl diphosphate, Fluorescence detection, Geranyl diphosphate, Geranylgeranyl diphosphate, High performance liquid chromatography, isoprenylation, Isoprenoid",
author = "Holstein, {Sarah A.} and Huaxiang Tong and Kuder, {Craig H.} and Hohl, {Raymond J.}",
year = "2009",
month = "11",
day = "1",
doi = "10.1007/s11745-009-3355-x",
language = "English (US)",
volume = "44",
pages = "1055--1062",
journal = "Lipids",
issn = "0024-4201",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Quantitative determination of geranyl diphosphate levels in cultured human cells

AU - Holstein, Sarah A.

AU - Tong, Huaxiang

AU - Kuder, Craig H.

AU - Hohl, Raymond J.

PY - 2009/11/1

Y1 - 2009/11/1

N2 - Geranyl diphosphate (GPP), a 10-carbon isoprenoid, is a key intermediate in the isoprenoid biosynthetic pathway. This pathway, in addition to leading to sterol synthesis, results in the synthesis of farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), which serve as substrates for protein isoprenylation reactions. Basal levels of GPP in mammalian cells previously have been undetectable. Here we present a novel, sensitive, nonradioactive method which allows for measurement of GPP in mammalian cells. This methodology involves extraction of isoprenoids from cultured cells followed by enzymatic conjugation of GPP to a fluorescent dansylated-peptide via farnesyl transferase and quantification with high-performance liquid chromatography (HPLC). The lower limit of detection of GPP is 5 pg, or 0.015 pmol. Basal levels of GPP were determined in three human multiple myeloma cell lines (RPMI-8226, U266, H929). Treatment of cells with inhibitors of the isoprenoid biosynthetic pathway results in marked changes in GPP levels: the HMG-CoA reductase inhibitor lovastatin decreases GPP levels by over 50%, while the FPP synthase inhibitor zoledronic acid increases GPP levels 16- to 107-fold. This method also allows for the simultaneous measurement of GPP, FPP, and GGPP, thus leading to improved understanding of the pathway in a multitude of biological systems. Furthermore, as drugs targeting this pathway are developed, their biological activity can be more directly linked to effects on isoprenoid levels.

AB - Geranyl diphosphate (GPP), a 10-carbon isoprenoid, is a key intermediate in the isoprenoid biosynthetic pathway. This pathway, in addition to leading to sterol synthesis, results in the synthesis of farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), which serve as substrates for protein isoprenylation reactions. Basal levels of GPP in mammalian cells previously have been undetectable. Here we present a novel, sensitive, nonradioactive method which allows for measurement of GPP in mammalian cells. This methodology involves extraction of isoprenoids from cultured cells followed by enzymatic conjugation of GPP to a fluorescent dansylated-peptide via farnesyl transferase and quantification with high-performance liquid chromatography (HPLC). The lower limit of detection of GPP is 5 pg, or 0.015 pmol. Basal levels of GPP were determined in three human multiple myeloma cell lines (RPMI-8226, U266, H929). Treatment of cells with inhibitors of the isoprenoid biosynthetic pathway results in marked changes in GPP levels: the HMG-CoA reductase inhibitor lovastatin decreases GPP levels by over 50%, while the FPP synthase inhibitor zoledronic acid increases GPP levels 16- to 107-fold. This method also allows for the simultaneous measurement of GPP, FPP, and GGPP, thus leading to improved understanding of the pathway in a multitude of biological systems. Furthermore, as drugs targeting this pathway are developed, their biological activity can be more directly linked to effects on isoprenoid levels.

KW - Farnesyl diphosphate

KW - Fluorescence detection

KW - Geranyl diphosphate

KW - Geranylgeranyl diphosphate

KW - High performance liquid chromatography, isoprenylation

KW - Isoprenoid

UR - http://www.scopus.com/inward/record.url?scp=70449533661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449533661&partnerID=8YFLogxK

U2 - 10.1007/s11745-009-3355-x

DO - 10.1007/s11745-009-3355-x

M3 - Article

C2 - 19856009

AN - SCOPUS:70449533661

VL - 44

SP - 1055

EP - 1062

JO - Lipids

JF - Lipids

SN - 0024-4201

IS - 11

ER -